Advisor Partners LLC grew its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 82.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,147 shares of the biopharmaceutical company’s stock after purchasing an additional 1,426 shares during the quarter. Advisor Partners LLC owned about 1,408.62% of Alexion Pharmaceuticals worth $441,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALXN. Fiduciary Trust Co. purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth about $111,000. Huntington National Bank grew its position in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 987 shares during the period. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter worth about $156,000. BT Investment Management Ltd purchased a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter worth about $165,000. Finally, Penserra Capital Management LLC grew its position in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 144 shares during the period. Institutional investors and hedge funds own 94.60% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $2.84 during midday trading on Wednesday, hitting $114.58. 1,048,459 shares of the stock were exchanged, compared to its average volume of 2,392,349. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The stock has a market cap of $25,902.11, a P/E ratio of 23.71, a PEG ratio of 1.27 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.23 EPS. equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current fiscal year.

A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Royal Bank Of Canada upped their target price on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Stifel Nicolaus reduced their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $182.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $154.01.

In other news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Julie O’neill sold 4,375 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the sale, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,490 shares of company stock worth $2,337,251. Insiders own 4.35% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Advisor Partners LLC Raises Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/08/advisor-partners-llc-raises-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.